27 August 2024 - Ipsen has entered into an agreement to sell its rare paediatric disease priority review voucher to a large global pharmaceutical company. 

Ipsen received the voucher coinciding with the Sohonos (palovarotene) US FDA approval.

Read Ipsen press release